Skip to content
drillr.ai
Sign up

TNXP

Tonix Pharmaceuticals Holding Corp.

NASDAQ · Healthcare · Biotechnology · US

$5.73
−5.13%
Ask drillr

  • Oct 19, 2026, 11:00 UTC

    Tonix Pharmaceuticals announced that a poster analyzing Phase 3 data on TONMYA will be presented at the IASP 2026 World Congress on Pain in Bangkok from October 26 to 30, 2026.

    Source:

  • Oct 15, 2026, 11:00 UTC

    Tonix Pharmaceuticals announced an oral presentation on its investigational TNX-801 vaccine platform and a working group session it will lead at the World Vaccine Congress Europe in Amsterdam on October 19–21, 2026.

    Source:

  • Oct 11, 2026, 23:59 UTC

    Tonix Pharmaceuticals Holding Corp. broke ground on a 44-acre manufacturing facility in Hamilton, Montana, intended to produce its TNX-4800 Lyme disease prophylactic.

    Source:

  • Sep 22, 2026, 11:00 UTC

    Tonix Pharmaceuticals announced a second major managed Medicare payer agreement for its fibromyalgia treatment TONMYA, effective immediately, adding approximately 21 million Medicare lives.

    Source:

  • Sep 8, 2026, 11:00 UTC

    Tonix Pharmaceuticals promoted Thomas Englese to Chief Commercial Officer, effective immediately on September 8, 2026.

    Source:

  • Aug 18, 2026, 07:02 UTC

    Tonix Pharmaceuticals is focusing on the commercial launch of TONMYA for fibromyalgia.

    Source:

  • Aug 18, 2026, 00:00 UTC

    Dr. Seth Lederman was appointed Interim Chief Medical Officer of Tonix Pharmaceuticals Holding Corp., effective August 18, 2026, while continuing as President, Chief Executive Officer and Chairman of the Board.

  • Aug 10, 2026, 11:00 UTC

    Tonix Pharmaceuticals reported second quarter 2026 financial results, with TONMYA net sales of approximately $11 million, up 197% quarter-over-quarter, and cash and cash equivalents of approximately $176.2 million as of June 30, 2026.

    Source:

  • Aug 3, 2026, 11:00 UTC

    Tonix Pharmaceuticals announced positive minutes from a Type C FDA meeting regarding the adaptive Phase 2 field study of TNX-4800, a human anti-OspA monoclonal antibody to prevent Lyme disease in the U.S.

    Source:

  • Jul 13, 2026, 11:00 UTC

    Tonix Pharmaceuticals announced a managed Medicare payer agreement for TONMYA, effective January 1, 2027, covering approximately 9 million Medicare lives.

    Source:

  • Jun 8, 2026, 12:41 UTC

    Tonix Pharmaceuticals secured a second commercial payer agreement for its fibromyalgia treatment TONMYA.

    Source: